Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection

Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials

(2013) Kathleen M. Mullane et al.   AMERICAN JOURNAL OF NEPHROLOGY

Comparative Effectiveness ofClostridium difficileTreatments

(2013) Dimitri M. Drekonja et al.   ANNALS OF INTERNAL MEDICINE

Advances in the treatment ofClostridium difficilewith fidaxomicin: a narrow spectrum antibiotic

(2013) Pamela Sears et al.   Annals of the New York Academy of Sciences

Is Fidaxomicin Worth the Cost? An Economic Analysis

(2013) Sarah M. Bartsch et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection

(2013) S.B. Debast et al.   CLINICAL MICROBIOLOGY AND INFECTION

Resolution of Clostridium difficile–Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin

(2013) Oliver A. Cornely et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Age on Treatment Outcomes inClostridium difficileInfection

(2013) Thomas J. Louie et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States

(2013) Paul M. Stranges et al.   VALUE IN HEALTH

ComparativeIn VitroActivities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

(2012) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores

(2012) Charlotte A. Allen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: a Multicenter Study in Taiwan

(2012) Chun-Hsing Liao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

(2012) T. J. Louie et al.   CLINICAL INFECTIOUS DISEASES

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection

(2012) M. M. Nerandzic et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Inhibits Spore Production in Clostridium difficile

(2012) Farah Babakhani et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial Activities of Fidaxomicin

(2012) Ellie J. C. Goldstein et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis

(2012) Irina Artsimovitch et al.   CLINICAL INFECTIOUS DISEASES

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin

(2012) I. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

(2012) Laurica A. Petrella et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

(2012) Derrick W. Crook et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection

(2012) P. Sears et al.   CLINICAL INFECTIOUS DISEASES

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

(2012) O. A. Cornely et al.   CLINICAL INFECTIOUS DISEASES

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?

(2012) O.A. Cornely   CLINICAL MICROBIOLOGY AND INFECTION

Fidaxomicin: a new option for the treatment of Clostridium difficile infection

(2012) A. P. Johnson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin inhibits toxin production in Clostridium difficile

(2012) F. Babakhani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Clostridium difficile Infection: New Insights Into Management

(2012) Sahil Khanna et al.   MAYO CLINIC PROCEEDINGS

PIN35 Decision Analysis Model Evaluating the Cost-Effectiveness of Fidaxomicin and Vancomycin in the Treatment of Clostridium Difficile Infection (CDI) from a Hospital Perspective

(2012) M.S. Alowayesh et al.   VALUE IN HEALTH

PGI21 a Comparison of the Cost-Effectiveness of Fidaxomicin, Metronidazole, and Vancomycin, in the Treatment of Clostridium Difficile-Associated Disease

(2012) N. Madkour et al.   VALUE IN HEALTH

Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures

(2012) Jane A. Cecil   Current Infectious Disease Reports

Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile

(2011) Farah Babakhani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

(2011) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

(2011) Kathleen M. Mullane et al.   CLINICAL INFECTIOUS DISEASES

Recurrent Clostridium difficile Infection

(2011) Claire M.F. van Nispen tot Pannerden et al.   DRUGS

Fidaxomicin

(2011) Sean T. Duggan   DRUGS

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

(2011) F. Babakhani et al.   JOURNAL OF MEDICAL MICROBIOLOGY

The Search for Effective Treatment ofClostridium difficileInfection

(2011) Herbert L. DuPont   NEW ENGLAND JOURNAL OF MEDICINE

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile

(2010) F. Babakhani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

(2008) Y. K. Shue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY